Aclaris Therapeutics (NASDAQ: ACRS) posts new corporate overview presentation online for investors

Rhea-AI Filing Summary

Aclaris Therapeutics, Inc. furnished an updated corporate overview presentation as part of a current report under Regulation FD. The presentation is attached as Exhibit 99.1 and is also available on the company’s website, providing an overview of its business for investors and other stakeholders. The company states that this material is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings unless specifically referenced.

0001557746false00015577462026-01-122026-01-12

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): January 12, 2026

​

​

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware	​	001-37581	​	46-0571712
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)

​

701 Lee Road, Suite 103

Wayne, PA 19087

(Address of principal executive offices, including zip code)

​

(484) 324-7933

(Registrant’s telephone number, including area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act: 

​

Title of Each Class:	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of Each Exchange on which Registered
Common Stock, $0.00001 par value		ACRS		The Nasdaq Stock Market, LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, Aclaris Therapeutics, Inc. (the “Company”) updated its corporate overview presentation, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The updated corporate overview presentation is also available on the Company’s website.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

​

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
Number		Exhibit Description
99.1	​	Company Presentation.
104		The cover page from Aclaris Therapeutics, Inc.’s Form 8-K filed on January 12, 2026, formatted in Inline XBRL.

​

​

​

​

​

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	ACLARIS THERAPEUTICS, INC.
​	​	​
​	By:	/s/ Kevin Balthaser
Date: January 12, 2026	​	Kevin Balthaser
​	​	Chief Financial Officer

​

​

3

FAQ

What did Aclaris Therapeutics (ACRS) disclose in this 8-K?

Aclaris Therapeutics furnished an updated corporate overview presentation, which is attached as Exhibit 99.1 and made available on its website.

Where can investors find the new Aclaris Therapeutics corporate presentation?

The updated corporate overview presentation is included as Exhibit 99.1 to the current report and is also available on Aclaris Therapeutics, Inc.’s website.

How is the Aclaris Therapeutics presentation treated under SEC rules?

The company states the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not deemed filed under Section 18 of the Exchange Act or automatically incorporated into other filings unless specifically referenced.

Which exhibit contains the Aclaris Therapeutics corporate overview?

Exhibit 99.1 contains the updated Aclaris Therapeutics, Inc. corporate overview presentation described in the current report.

Does this Aclaris Therapeutics 8-K include financial statements?

The current report lists Exhibit 99.1 as the company presentation and Exhibit 104 as the cover page formatted in Inline XBRL; it does not present separate financial statements in the excerpt provided.